Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Bone Density Conservation Agents

Hematinics

Vitamins

Paclitaxel

Leucovorin

Fluorouracil

Levoleucovorin

Albumin-Bound Paclitaxel

Oxaliplatin

Calcium

Calcium, Dietary

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folinic Acid

Folate

Vitamin B9

The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed

The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.

The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.

Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU

FOLFOX

FOLFOX plus PAC(ip)

Rongbo Lin, MD

The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.

The biweekly 5-fluorouracil and leucovorin (LV5FU2) regimen associated with oxaliplatin (FOLFOX) is active in patients with AGC. Meanwhile, Paclitaxel monotherapy is also active in patients with AGC. In previous studies, we found that POF(A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer. This study is being done to find out if three drugs combination maintain manageable side effects but have better benefit than two drugs combination. Intraperitoneal paclitaxel showed high local concentration in abdominal cavity and low systemic toxicity. This study is being done to find out if the combination with Intraperitoneal paclitaxel and FOLFOX have higher local control rate and lower systemic toxicity.

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer

The length of time from enrollment until the time of progression of disease (PFS, progression-free survival).

Response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Clinical response of treatment according to RESIST v1.1 criteria (ORR, According to NCI CTCAE 4.03 criteria

a quality-of-life instrument for use in international clinical trials in oncology.

EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy

The length of time from enrollment until the time of death (OS, overall survival

Fujian Cancer Hospital

Symptoms and General Pathology

Neoplasm Metastasis

The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.

POF Versus FOLFOX Plus IP Paclitaxel in AGC

A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer With Peritoneal Metastases

The length of time from enrollment until the time of death

Adverse Event according to NCI CTCAE 5 criteria

Clinical response of treatment according to RESIST v1.1 criteria

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC	NCT02845908	Malignant Neopl...	POF FOLFOX FOLFOX plus PAC...	18 Years - 75 Years	Fujian Cancer Hospital
POF Versus FOLFOX Plus IP Paclitaxel in AGC	NCT04155671	Gastric Cancer	POF FOLFOX plus PAC...	18 Years - 75 Years	Fujian Cancer Hospital
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC	NCT02845908	Malignant Neopl...	POF FOLFOX FOLFOX plus PAC...	18 Years - 75 Years	Fujian Cancer Hospital

Spots Global Cancer Trial Database for folfox plus pac(ip)